About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Protein Helps Identify People With Greater Risk of Heart Failure

by Kathy Jones on September 1, 2012 at 3:10 PM
Font : A-A+

 Protein Helps Identify People With Greater Risk of Heart Failure

Researchers at by the National Heart, Lung, and Blood Institute (NHLBI) have identified a protein known as galectin-3 that can help identify people who have a higher risk of suffering from heart failure.

This research is based on work from the NHLBI's Framingham Heart Study, which began in 1948 and has been the leading source of research findings about heart disease risk factors.

Advertisement

"Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community," will be published online August 29 in the Journal of the American College of Cardiology and in the October 2 print issue.

Heart failure occurs when the heart cannot fill with enough blood and/or pump enough blood to meet the body's needs. Galactin-3 has recently been associated with cardiac fibrosis, a condition in which scar tissue replaces heart muscle, and cardiac fibrosis plays an important role in the development of heart failure.
Advertisement

Heart failure carries enormous risk for death or a lifetime of disability and often there are few warning signs of impending heart failure. Measuring levels of galectin-3 in the blood may offer a way to identify high-risk individuals who could benefit from treatments to prevent debilitating heart failure and death. Early identification of predisposed individuals would allow treatment to begin long before heart failure develops and could help people at high risk for heart failure to live longer, more active lives.

Galectin-3 levels were measured in 1996-1998 as part of a routine examination of 3,353 participants enrolled in the Offspring Cohort of the Framingham Heart Study. At the time of measurement the average age of the participants was 59 years old. During an average follow-up of 11 years, 166 participants (5.1 percent) had a first heart failure event. Among the 25 percent of people with the highest galectin-3 levels (ranging from 15.4 to 52.1 nanograms per milliliter) the annual rate of heart failure was 12 per 1,000 people compared with 3 per 1,000 people for the 25 percent of participants with the lowest galectin-3 levels (ranging from 3.9 to 12 nanograms per milliliter). Fifty-three percent of participants were women.

Spironolactone and other related drugs believed to counteract cardiac fibrosis have been shown to improve outcomes in heart failure patients. Future research will be needed to determine whether treatment with these or other drugs can benefit healthy patients with elevated galectin-3 levels.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Congenital Heart Disease Heart Healthy Heart Pulmonary Arterial Hypertension Statins Mitral Valve Prolapse Aortic Valve Stenosis Infective Endocarditis Magical Millets for Your Health Cough Symptom Evaluation 

Most Popular on Medindia

Noscaphene (Noscapine) Hearing Loss Calculator How to Reduce School Bag Weight - Simple Tips Pregnancy Confirmation Calculator The Essence of Yoga Accident and Trauma Care Drug - Food Interactions Vent Forte (Theophylline) Drug Interaction Checker Indian Medical Journals
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use